The Latest
-
Deep DiveGive up board chairmanship? No thanks, US big pharma CEOs say
Pfizer CEO Albert Bourla will soon head the pharma's board, too, adding another example of a large drugmaker with unified leadership.
-
SponsoredFace-to-face vs. digital promotion: Finding the right balance
Assess your customer-facing model against these five key factors to increase customer satisfaction and engagement.
-
Sanofi investing in gene therapy as R&D focus turns toward rare disease
R&D chief John Reed told BioPharma Dive Sanofi is retrofitting a vaccine facility in France to produce the viral vectors needed to deliver gene therapies.
-
Alexion bids for a smaller version of itself, spurring concerns about the FTC
With the Roche-Spark deal in limbo, analysts are concerned that companies with overlapping pipelines may have trouble completing acquisitions.
-
Novartis backs away from marketing Pear digital therapeutics
While Sandoz and Pear are still working together, the Swiss pharma unit will no longer co-promote the recently launched reSET and reSET-O.
-
Lilly cancer drug pipeline hit by trial setback
Pegilodecakin, an immunotherapy acquired in the pharma's $1.6 billion deal for Armo BioSciences, failed to extend survival in patients with pancreatic cancer.
-
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Newly launched as Ichnos, the spin-out company is led by former Gilead oncology chief Alessandro Riva.
-
Reata surprises with positive data in challenging rare disease
There are no FDA-approved drugs for Friedreich's Ataxia, an uncommon neurological disorder. Reata looks closer to changing that with its latest data.
-
Sanofi upgrades biotech manufacturing with new Massachusetts plant
The French pharma has spent about $320 million over the past five years on the facility, part of a broader effort to retool how it makes the drugs it sells.
-
Pelosi drug plan would save $370B, but could reduce R&D, forecasters say
Pharma would respond to Pelosi's proposal by raising list prices, keeping some drugs off foreign markets, and cutting R&D spending, according to the CBO.
-
Lilly shuttering UK neuroscience research site
Most employees will be relocated to a new facility in the area, although Lilly expects to lay off as many as 80 workers.
-
Revance CEO stepping down over 'misjudgment'
Dan Browne, who has led Revance for the past 17 years, will be replaced by board member and former Zeltiq CEO Mark Foley.
-
Gene therapy biotechs caught in manufacturing crunch
Rising demand for contract manufacturing services could push companies to invest more in their own capabilities despite the high cost.
UPDATED: Oct. 11, 2019 at 10:49 a.m. -
Lilly's 1-drug migraine business gets support with new approval
An OK for Reyvow, an acute migraine drug, complements Lilly's preventive therapy Emgality and could strengthen the company's footing in an increasingly crowded market.
-
On second thought, AbbVie's new arthritis drug not so costly, ICER says
A re-evaluation of Rinvoq makes it look like a better value, although the group's estimate says it offers "marginal clinical benefit" compared to Humira.
-
Five Prime's restructuring claims more jobs
Roughly 70 jobs will be eliminated, leaving a "small research group" to develop the California biotech's three wholly-owned drugs.
-
UCB bets more on rare disease drugs with Ra Pharma acquisition
The $2.5 billion deal hands UCB another late-stage drug for generalized myasthenia gravis, a disease area dominated by Alexion Pharmaceuticals.
-
Reata buys drug rights back from AbbVie for $330M before readout
"It shows our confidence, but we'll have to see how the data plays out," the biotech's CFO told BioPharma Dive.
-
ProQR eye-disease data lend confidence that pivotal trial will succeed
The positive data also helps to keep the Netherlands drugmaker ahead of gene-editing specialists Editas and its partner, Allergan.
-
Feeling pressure in hemophilia, Novo signs gene editing deal with Bluebird
The deal may come too late, though, as the launch of Hemlibra and approach of gene therapies dampens demand for Novo's factor replacement therapies.
-
J&J hit with $8B jury verdict over Risperdal as legal troubles mount
The multi-billion dollar payment stems from claims J&J illegally marketed its blockbuster antipsychotic, which was linked to lasting side effects.
-
With new report, ICER puts itself at center of drug pricing storm
Pharma price hikes added billions of dollars to U.S. spending in 2017 and 2018. For seven top drugs, the watchdog found those increases came with little new clinical evidence in support.
UPDATED: Oct. 8, 2019 at 1:03 p.m. -
Former FDA chief Gottlieb predicts Trump-pitched pricing model easy to game
"I don't want to give too much away, because I'll tell people how to game around this," said the former commissioner, who now sits on Pfizer's board.
-
Australian drugmaker's decade-long journey ends in FDA approval
U.S. regulators cleared Clinuvel's Scenesse for a rare skin disease that causes sensitivity to light.
-
FDA leaders worry agency will lose out on talent in gene therapy, cancer fields
Peter Marks, director of the FDA's biologics center, said the agency is competing with industry to keep its staff.
